MRI T2 Hypointensities in basal ganglia of premanifest Huntington's disease

PLoS Currents

Volumn , Issue AUG, 2010, Pages 1-15

  Jurgens, Caroline K ^a,b   Jasinschi, Radu ^c   Ekin, Ahmet ^c   Witjes Ané, Marie Noëlle W ^a,b   van der Grond, Jeroen ^a   Middelkoop, Huub ^a   Roos, Raymund A C ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MEDICAL CENTER HAAGLANDEN   (Netherlands)

^c PHILIPS RESEARCH LABORATORIES   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84873461127     PISSN: None     EISSN: 21573999     Source Type: Journal    
DOI: 10.1371/currents.RRN1173     Document Type: Article

References (31)

1. Bates G, Harper PS, Jones L. Huntington's disease, Third ed. Oxford University Press, 2002.
2. Berg D, Gerlach M, Youdim MB, et al. Brain iron pathways and their relevance to Parkinson's disease. J Neurochem 2001; 79:225-236.
3. Zecca L, Youdim MB, Riederer P, et al. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 2004; 5:863-873.
4. Gotz ME, Double K, Gerlach M, et al. The relevance of iron in the pathogenesis of Parkinson's disease. Ann N Y Acad Sci 2004; 1012:193-208.
5. Dexter DT, Carayon A, Javoy-Agid F, et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991; 114:1953-1975.
6. Chen JC, Hardy PA, Kucharczyk W, et al. MR of human postmortem brain tissue: correlative study between T2 and assays of iron and ferritin in Parkinson and Huntington disease. AJNR Am J Neuroradiol 1993; 14:275-281.
7. Simmons DA, Casale M, Alcon B, et al. Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington's disease. Glia 2007; 55:1074-1084.
8. Schenck JF, Zimmerman EA. High-field magnetic resonance imaging of brain iron: birth of a biomarker? Nmr in Biomedicine 2004; 17:433-445.
9. van Es AC, van der Grond J, de Craen AJ, et al. Caudate nucleus hypointensity in the elderly is associated with markers of neurodegeneration on MRI. Neurobiol Aging 2008; 29:1839-1846.
10. Vymazal J, Klempir J, Jech R, et al. MR relaxometry in Huntington's disease: correlation between imaging, genetic and clinical parameters. J Neurol Sci 2007; 263:20-25.
11. Drayer B, Burger P, Darwin R, et al. MRI of brain iron. AJR Am J Roentgenol 1986; 147:103-110.
12. Haacke EM, Cheng NY, House MJ, et al. Imaging iron stores in the brain using magnetic resonance imaging. Magn Reson Imaging 2005; 23:1-25.
13. Schenker C, Meier D, Wichmann W, et al. Age distribution and iron dependency of the T2 relaxation time in the globus pallidus and putamen. Neuroradiology 1993; 35:119-124.
14. Bartzokis G, Cummings J, Perlman S, et al. Increased basal ganglia iron levels in Huntington disease. Arch Neurol 1999; 56:569-574.
15. Bartzokis G, Tishler TA. MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer's and Huntingon's disease. Cell Mol Biol (Noisy-le-grand) 2000; 46:821-833.
16. Bartzokis G, Lu PH, Tishler TA, et al. Myelin breakdown and iron changes in Huntington's disease: Pathogenesis and treatment implications. Neurochemical Research 2007; 32:1655-1664.
17. American College of Medical Genetics/American Society of Human Genetics Huntington Disease Genetic Testing Working Group. ACMG/ASHG statement Laboratory guidelines for Huntington disease genetic testing. American Journal of Human Genetics 1998; 62:1243-1247.
18. Langbehn DR, Brinkman RR, Falush D, et al. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clinical Genetics 2004; 66:81.
19. Kieburtz K, Penney JB, Como P, et al. Unified Huntington's disease rating scale: Reliability and consistency. Movement Disorders 1996; 11:136-142.
20. Witjes-Ané MNW, Zwinderman AH, Tibben A, et al. Behavioural complaints in participants who underwent predictive testing for Huntington's disease. Journal of Medical Genetics 2002; 39:857-862.
21. Talairach J, Tournoux P. Co-planar stereotaxic atlas of the human brain. New York: Thieme, 1998.
22. Smith SM, Rao A, De Stefano N, et al. Longitudinal and cross-sectional analysis of atrophy in Alzheimer's disease: cross-validation of BSI, SIENA and SIENAX. Neuroimage 2007; 36:1200-1206.
23. Jurgens CK, van de Wiel L, van Es AC, et al. Basal ganglia volume and clinical correlates in 'preclinical' Huntington's disease. J Neurol 2008; 255:1785-1791.
24. Stankiewicz JM, Brass SD. Role of iron in neurotoxicity: a cause for concern in the elderly? Current Opinion in Clinical Nutrition and Metabolic Care 2009; 12:22-29.
25. Brass SD, Chen NK, Mulkern RV, et al. Magnetic resonance imaging of iron deposition in neurological disorders. Top Magn Reson Imaging 2006; 17:31-40.
26. Hallgren B, Sourander P. The effect of age on the non-haemin iron in the human brain. J Neurochem 1958; 3:41-51.
27. Bartzokis G, Tishler TA, Shin IS, et al. Brain ferritin iron as a risk factor for age at onset in neurodegenerative diseases. Redox-Active Metals in Neurological Disorders 2004; 1012:224-236.
28. Hill JM, Ruff MR, Weber RJ, et al. Transferrin receptors in rat brain: neuropeptide-like pattern and relationship to iron distribution. Proc Natl Acad Sci U S A 1985; 82:4553-4557.
29. Hilditch-Maguire P, Trettel F, Passani LA, et al. Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles. Hum Mol Genet 2000; 9:2789-2797.
30. Ke Y, Ming QZ. Iron misregulation in the brain: a primary cause of neurodegenerative disorders. Lancet Neurol 2003; 2:246-253.
31. Zhang J, Zhang Y, Wang J. et al. Characterizing iron deposition in Parkinson's disease using susceptibilityweighted imaging: An in vivo MR study. Brain Research 2010; 1330:124-130.